Development of a locally advanced orthotopic prostate tumor model in rats for assessment of combined modality therapy

International Journal of Oncology

Volumn 42, Issue 5, 2013, Pages 1613-1619

  Tumati, Vasu ^a   Mathur, Sanjeev ^c   Song, Kwang ^a   Hsieh, Jer Tsong ^a,d   Zhao, Dawen ^a,d   Takahashi, Masaya ^b   Dobin, Timothy ^a   Gandee, Leah ^a   Solberg, Timothy D ^a,d   Habib, Amyn A ^a,d   Saha, Debabrata ^a,d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Animal MRI; Prostate cancer; Radioresistance; Ultra sound and image guided radiation therapy

Indexed keywords

ANTINEOPLASTIC AGENT; DAB2IP PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CONTROLLED STUDY; FIDUCIAL MARKER; HUMAN; HUMAN CELL; IMAGE GUIDED RADIOTHERAPY; IMPLANTATION; MINIMALLY INVASIVE PROCEDURE; MULTIMODALITY CANCER THERAPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE TUMOR; RAT; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR VOLUME; ULTRASOUND;

ANIMALS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIOTHERAPY, IMAGE-GUIDED; RAS GTPASE-ACTIVATING PROTEINS; RATS;

EID: 84875973015     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1858     Document Type: Article

References (21)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. Coen JJ, Zietman AL, Thakral H and Shipley WU: Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases. J Clin Oncol 20: 3199-3205, 2002. (Pubitemid 34831515)
3. Li T, Thongphiew D, Zhu X, et al: Adaptive prostate IGRT combining online re-optimization and re-positioning: a feasibility study. Phys Med Biol 56: 1243-1258, 2011.
4. De Crevoisier R, Tucker SL, Dong L, et al: Increased risk of biochemical and local failure in patients with distended rectum on the planning CT for prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 62: 965-973, 2005. (Pubitemid 40884405)
5. Kong Z, Xie D, Boike T, et al: Downregulation of human DAB2IP gene expression in prostate cancer cells results in resistance to ionizing radiation. Cancer Res 70: 2829-2839, 2010.
6. Kong Z, Raghavan P, Xie D, et al: Epothilone B confers radiation dose enhancement in DAB2IP gene knock-down radioresistant prostate cancer cells. Int J Radiat Oncol Biol Phys 78: 1210-1218, 2010.
7. Pidikiti R, Stojadinovic S, Speiser M, et al: Dosimetric characterization of an image-guided stereotactic small animal irradiator. Phys Med Biol 56: 2585-2599, 2011.
8. Saha D, Watkins L, Yin Y, et al: An orthotopic lung tumor model for image-guided microirradiation in rats. Radiat Res 174: 62-71, 2010.
9. Xie D, Gore C, Zhou J, et al: DAB2IP coordinates both PI3K-Akt and ASK1 pathways for cell survival and apoptosis. Proc Natl Acad Sci USA 106: 19878-19883, 2009.
10. Xie D, Gore C, Liu J, et al: Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis. Proc Natl Acad Sci USA 107: 2485-2490, 2010.
11. Raheem O, Kulidjian AA, Wu C, et al: A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions. J Transl Med 9: 185, 2011.
12. Shikanov S, Shikanov A, Gofrit O, Nyska A, Corn B and Domb AJ: Intratumoral delivery of paclitaxel for treatment of orthotopic prostate cancer. J Pharm Sci 98: 1005-1014, 2009.
13. Tse BW, Russell PJ, Lochner M, Forster I and Power CA: IL-18 inhibits growth of murine orthotopic prostate carcinomas via both adaptive and innate immune mechanisms. PLoS One 6: e24241, 2011.
14. Dunning WF: Prostate cancer in the rat. Natl Cancer Inst Monogr 12: 351-369, 1963.
15. Lubaroff DM and Culp DA: Experience with an animal model for the study of prostatic carcinoma. Trans Am Assoc Genitourin Surg 69: 72-77, 1977.
16. Lubaroff DM, Canfield L, Feldbush TL and Bonney WW: R3327 adenocarcinoma of the Copenhagen rat as a model for the study of the immunologic aspects of prostate cancer. J Natl Cancer Inst 58: 1677-1689, 1977. (Pubitemid 8118744)
17. Lopez DM and Voigt W: Adenocarcinoma R-3327 of the Copenhagen rat as a suitable model for immunological studies of prostate cancer. Cancer Res 37: 2057-2061, 1977.
18. Vieweg J, Rosenthal FM, Bannerji R, et al: Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res 54: 1760-1765, 1994. (Pubitemid 24116182)
19. Rao BR, Slotman BJ, Geldof AA and Perez CA: Radiation sensitivity of Copenhagen rat prostatic carcinoma (R3327-AT and R3327-MATLyLu). Int J Radiat Oncol Biol Phys 20: 981-985, 1991.
20. Vaupel P, Kallinowski F and Okunieff P: Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 49: 6449-6465, 1989. (Pubitemid 20008770)
21. Szentirmai O, Baker CH, Lin N, et al: Noninvasive bioluminescence imaging of luciferase expressing intracranial U87 xenografts: correlation with magnetic resonance imaging determined tumor volume and longitudinal use in assessing tumor growth and antiangiogenic treatment effect. Neurosurgery 58: 365-372, 2006. (Pubitemid 43212802)